Xencor Drug Shows Unprecedented Profile in Colorectal Cancer: Analyst

기사 요약

Xencor reports upbeat Phase 1 kidney cancer data for XmAb819 at ESMO 2026 and selects 400 mcg/kg as the primary proposed Phase 3 study dose.